MEDICAL POLICY

POLICY
RELATED POLICIES
POLICY GUIDELINES
DESCRIPTION
SCOPE
BENEFIT APPLICATION
RATIONALE
REFERENCES
CODING
APPENDIX
HISTORY

Microwave Tumor Ablation

Number 7.01.133

Effective Date December 17, 2014

Revision Date(s) 12/08/14; 12/09/13; 04/08/13

Replaces N/A

Policy

Microwave ablation (MWA) of primary and metastatic tumors is considered investigational.

Related Policies

7.01.95

Radiofrequency Ablation of Miscellaneous Solid Tumors Excluding Liver Tumors

7.01.526

Cryosurgical Ablation of Miscellaneous Solid Tumors Other Than Liver, Prostate, or Dermatologic Tumors

8.01.505

Transcatheter Arterial Chemoembolization as a Treatment for Primary or Metastatic Liver Malignancies

8.01.521

Radioembolization for Primary and Metastatic Tumors of the Liver

Policy Guidelines

There are no CPT codes specific to microwave ablation.

According to a 2012 American Medical Association publication (Clinical Examples in Radiology, Vol. 8, Issue 3; Summer 2012), “microwave is part of the radiofrequency spectrum, and simply uses a different part of the radiofrequency spectrum to develop heat energy to destroy abnormal tissue.” Therefore, they instruct that microwave ablation should be reported using the CPT codes for radiofrequency ablation – 32998 (pulmonary), 47382 (liver), and 50592 (renal).

If there is no specific CPT code for ablation, the unlisted CPT code for the anatomic area should be reported such as code60699 for Unlisted procedure, endocrine system (for adrenal or thyroid ablation).

Description

Microwave ablation (MWA) is a technique to destroy tumors and soft tissue by using microwave energy to create thermal coagulation and localized tissue necrosis. MWA is used to treat tumors considered to be inoperable or not amenable to resection or to treat patients ineligible for surgery due to age, presence of comorbidities, or poor general health. MWA may be performed as an open procedure, laparoscopically, percutaneously, or thoracoscopically under image guidance (e.g., ultrasound, computed tomography or magnetic resonance imaging) with sedation, or local or general anesthesia. This technique may also be referred to as microwave coagulation therapy.

Background

MWA is a technique in which the use of microwave energy induces an ultra-high speed, 915 MHz or 2.450 MHz (2.45 GHz), alternating electric field, which causes water molecule rotation and the creation of heat. This results in thermal coagulation and localized tissue necrosis. In MWA, a single microwave antenna or multiple antennas connected to a generator are inserted directly into the tumor or tissue to be ablated; energy from the antennas generates friction and heat. The local heat coagulates the tissue adjacent to the probe, resulting in a small, approximately 2- to 3 -cm elliptical area (5 x 3 cm) of tissue ablation. In tumors greater than 2 cm in diameter, 2 to 3 antennas may be used simultaneously to increase the targeted area of MWA and shorten operative time. Multiple antennas may also be used simultaneously to ablate multiple tumors. Tissue ablation occurs quickly, within 1 minute after a pulse of energy, and multiple pulses may be delivered within a treatment session, depending on the size of the tumor. The cells killed by MWA are typically not removed but are gradually replaced by fibrosis and scar tissue. If there is local recurrence, it occurs at the edges. Treatment may be repeated as needed. MWA may be used to: 1) control local tumor growth and prevent recurrence; 2) palliate symptoms; and 3) extend survival duration.

Complications from MWA are usually considered mild and may include pain and fever. Other potential complications associated with MWA include those caused by heat damage to normal tissue adjacent to the tumor (e.g., intestinal damage during MWA of the kidney or liver), structural damage along the probe track (e.g., pneumothorax as a consequence of procedures on the lung), liver enzyme elevation, liver abscess, ascites, pleural effusion, diaphragm injury or secondary tumors if cells seed during probe removal. MWA should be avoided in pregnant patients because potential risks to the patient and/or fetus have not been established and in patients with implanted electronic devices such as implantable pacemakers that may be adversely affected by microwave power output.

MWA is an ablative technique similar to radiofrequency or cryosurgical ablation. However, MWA has some potential hypothetical advantages over RFA or cryosurgical ablation. In MWA, the heating process is active, which produces higher temperatures than the passive heating of RFA and should allow for more complete thermal ablation in a shorter period of time. The higher temperatures reached with MWA (over 100° C) can overcome the “heat sink” effect in which tissue cooling occurs from nearby blood flow in large vessels, potentially resulting in incomplete tumor ablation. MWA does not rely on the conduction of electricity for heating, and therefore, does not have electrical current flow through patients and does not require that grounding pads be used during the procedure, because there is no risk of skin burns. Additionally, MWA does not produce electric noise, which allows ultrasound guidance to occur during the procedure without interference, unlike RFA. Finally, MWA can be completed in less time than RFA, because multiple antennas can be used simultaneously.

MWA was first used percutaneously in 1986 as an adjunct to liver biopsy. Since that time, MWA has been used for ablation of tumors and tissue for the treatment of many conditions including: HCC, colorectal cancer metastatic to the liver, renal cell carcinoma, renal hamartoma, adrenal malignant carcinoma, non-small cell lung cancer, intrahepatic primary cholangiocarcinoma, secondary splenomegaly and hypersplenism, abdominal tumors and other tumors not amenable to resection. Well-established local or systemic treatment alternatives are available for each of these malignancies. The hypothesized advantages of MWA for these cancers include improved local control and those common to any minimally invasive procedure (e.g., preserving normal organ tissue, decreasing morbidity, decreasing length of hospitalization).

Hepatic Tumors

Hepatic tumors can arise either as primary liver cancer (HCC) or by metastasis to the liver from other primary cancer sites. Local therapy for hepatic metastasis may be indicated when there is no extrahepatic disease, which rarely occurs for patients with primary cancers other than colorectal carcinoma or certain neuroendocrine malignancies. At present, surgical resection with adequate margins or liver transplantation constitutes the only treatments available with demonstrated curative potential. Partial liver resection, hepatectomy, is considered the criterion standard. However, most hepatic tumors are unresectable at diagnosis, due either to their anatomic location, size, number of lesions, or underlying liver reserve.

Various locoregional therapies for unresectable liver tumors have been investigated including: microwave coagulation, RFA, cryosurgical ablation (cryosurgery), laser ablation, trans-hepatic artery embolization/chemoembolization (TACE), percutaneous ethanol injection, and radioembolization (Yttrium-90 microspheres).

MWA has been investigated as a treatment for unresectable hepatic tumors, both as primary treatment, palliative treatment, and as a bridge to liver transplant. In the latter setting, it is hoped that MWA will reduce the incidence of tumor progression while awaiting transplantation and thus maintain a patient’s candidacy for liver transplant during the wait time for a donor organ.

Renal Cell Carcinoma

Radical nephrectomy remains the principal treatment of renal cell carcinoma; however, partial nephrectomy or nephron-sparing surgery has been shown to be as effective as radical nephrectomy, with comparable long-term recurrence-free survival rates, in a select group of patients. Prognosis drops precipitously if the tumor extends outside the kidney capsule, because chemotherapy is relatively ineffective against metastatic renal cell carcinoma. Alternative therapies such as MWA are of interest in patients with small renal tumors when preservation of renal function is necessary (e.g., in patients with marginal renal function, a solitary kidney, bilateral tumors) and in patients with comorbidities that would render them unfit for surgery. Another consideration would be in patients at high risk of developing additional renal cancers (as in von Hippel-Lindau disease).

Regulatory Status

There are several devices cleared for marketing by FDA through the 510(k) process for MWA. Covidien’s (a subsidiary of Tyco Healthcare) Evident Microwave Ablation System has 510(k) clearance for soft tissue ablation, including partial or complete ablation of non-resectable liver tumors. The following devices have 510(k) clearance for MWA of (unspecified) soft tissue:

  • BSD Medical Corporation’s MicroThermX® Microwave Ablation System (MTX-180);
  • Valleylab’s (a subsidiary of Covidien) VivaWave® Microwave Ablation System;
  • Vivant’s (acquired by Valleylab in 2005) Tri-Loop™ Microwave Ablation Probe;
  • MicroSurgeon Microwave Soft Tissue Ablation Device;
  • Microsulis Medical’s (now part of AngioDynamics) Acculis® Accu2i; and
  • NeuWave Medical’s Certus 140™

These devices are considered substantially equivalent to previously FDA-approved radiofrequency and MWA devices. FDA product code: NEY.

This policy does not address MWA for the treatment of splenomegaly or ulcers or as a surgical coagulation tool.

Scope

Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.

Benefit Application

N/A

Rationale

The policy was created in 2011 and periodically updated with a literature reviews. The last literature review was conducted for the period of August 2013 through September 15, 2014. The findings of the literature review are summarized next with select studies.

Breast

A 2010 review of ablation techniques by Zhao et al. for breast cancer found only 0% to 8% of breast tumors were completely ablated with microwave ablation (MWA). (1) The authors noted the studies identified for the review were mostly feasibility and pilot studies conducted in research settings. In 2012, W. Zhou et al. reported on 41 patients treated with MWA directly followed by mastectomy for single breast tumors with a mean volume of 5.26±3.8 cm (range, 0.09-14.14 cm). (2) Complete tumor ablation was found by microscopic evaluation in 37 of the 41 tumors ablated (90%; 95% confidence interval [CI], 76.9% to 97.3%). Reversible thermal injuries to the skin and pectoralis major muscle occurred in 3 patients.

Hepatocellular Carcinoma

The literature search identified many publications on studies of MWA for hepatocellular carcinoma (HCC), primarily small case series and retrospective reviews conducted in China and Japan. Only two studies were indexed in the PubMed database as randomized controlled trials (RCTs). (3,4) No RCTs comparing the use of MWA for HCC with the criterion standard of surgical resection were identified. The following summarizes systematic reviews (5, 6) and select studies reporting on 25 or more patients. All of the studies demonstrated that the technique of MWA provided good tumor ablation (87%-100% ablation of targeted tumors) with low procedural complication rates. Associated morbidity and mortality, as well as overall survival (OS) and disease-free survival rates with MWA are similar to radiofrequency ablation (RFA), which would be an appropriate comparator in patients with tumors not amenable to surgical resection. However, only one RCT comparing MWA directly with RFA was identified. (3)

In 2009, Ong et al. conducted a systematic review of studies on MWA for primary and secondary liver tumors. (5) Based on the results from 25 clinical studies reporting outcomes on MWA, the authors concluded MWA is an effective and safe technique for liver tumor ablation with low complication rates and survival rates comparable with hepatic resection. However, rates of local recurrence after MWA were noted to be higher than hepatic resection. In most studies, HCC recurrence rates were approximately 10% but were also noted to be as high as 50%, which the authors indicated can be addressed with further ablation. Survival rates in the studies on MWA for HCC were as high as 92% at 3 years and 72% at 5 years, which was noted to be comparable with RFA and percutaneous ethanol injections. Pain and fever were the most frequently reported complications, but complications increased when there were more tumors, larger tumors, and more microwave antennas used. Ong et al. concluded MWA is a promising treatment option for the treatment of liver tumors but should be reserved for patients not amenable to hepatic resection. The authors also noted further RCTs are warranted to compare MWA with other ablation procedures. Bertot et al. conducted a systematic review in 2011 of ablation techniques for primary and secondary liver tumors. (6) This review included 2 studies using MWA totaling 1,185 patients. (7, 8) The pooled mortality rate for MWA was 0.23% (95% CI: 0.0% to 0.58%). Major complication rates were 4.6% for MWA (calculated by using a random effects model, because there was significant heterogeneity). The authors concluded percutaneous ablation techniques, including MWA, are safe and have acceptable complication rates for the treatment of liver tumors.

In 2002, Shibata et al. reported on 72 consecutive patients with 94 small HCC nodules randomized by sealed envelopes to receive either percutaneous MWA or RFA performed by a single surgeon. (3) No significant differences were identified between the 2 treatment group characteristics, e.g., sex, age, nodule size, Child-Pugh cirrhosis class and number of nodules. In the RFA group, complete therapeutic effect was seen in 46 (96%) of 48 nodules (mean size, 2.3 cm; range, 1.0-3.7) versus 41 (89%) of 46 nodules (mean size, 2.2 cm; range, 0.9-3.4) treated with percutaneous MWA (p=0.26). Treatment outcomes were not significantly different between the percutaneous MWA and RFA groups in the rates of untreated disease during a follow-up range of 6 to 27 months (8/46 nodules vs. 4/48 nodules, respectively), and major complication rates (4 vs. 1, respectively). Major complications included one case of segmental hepatic infarction in the RFA group. In the MWA group, major complications included one case of each of the following: liver abscess, cholangitis with intrahepatic bile duct dilatation, subcutaneous abscess with skin burn and subcapsular hematoma. Life-threatening complications were not experienced. The number of treatment sessions required per nodule in the RFA group was significantly lower than in the percutaneous MWA group (1.1 vs. 2.4; p<0.001). However, treatment time per session was significantly shorter in the MWA group (33±11 minutes) than the RFA group (53±16 minutes).

Taniai et al., in 2006, reported on 30 patients with multiple HCC tumors who underwent reduction hepatectomy with postoperative transcatheter arterial embolization. (4) Before surgery, patients were randomly assigned to receive no intraoperative adjuvant therapy (n=15) or intraoperative adjuvant therapy with either MWA (n=10) or RFA (n=5) of satellite lesions. No significant differences in characteristics were identified between the two treatment groups of no intraoperative adjuvant therapy vs. intraoperative adjuvant therapy, e.g., sex, age, nodule size (maximum tumor size, 42.7±23.5 mm vs. 37.8±16 mm, respectively), Child-Pugh cirrhosis class and number of nodules. Cumulative survival rates at 3 and 5 years were not significantly different in the group that did not receive intraoperative adjuvant therapy (35.0% and 0%, respectively) versus the intraoperative adjuvant therapy group (35.7% and 7.7%, respectively). A-fetoprotein, number of tumors, maximum tumor size, and clinical stage, but not intraoperative adjuvant therapy, were identified as independent prognostic survival factors.

In April 2011, Simo et al. retrospectively compared laparoscopic MWA (13 patients with 15 tumors) with RFA (22 patients with 27 tumors) performed by a single surgeon for the treatment of HCC. (9) No significant differences were identified between the two treatment group characteristics except for sex (54% vs. 86% male, respectively). Average tumor size was 2.31 cm in the MWA group versus 2.53 cm in the RFA group. The authors reported average tumor ablation volumes were not significantly different at 28.99 cm for MWA and 23.43 cm for RFA. In the MWA group, at a mean follow-up of 7 months, disease-free survival was 54%, with 2 patients having received liver transplants, 31% having disease progression and 15% deceased. The RFA group was followed for a longer period of time at a mean of 19 months. This group experienced 50% survival without evidence of disease, with 4 patients having received liver transplants, 9% having disease progression, 36% deceased, and 5% lost to follow-up. Operative times were shorter in the MWA group (112±40 vs. 149±35 minutes). In 2013, Ding et al. also reported on a retrospective comparison of 113 patients treated with MWA for 131 HCC tumors and 85 patients treated with RFA for 98 HCC tumors. (10) Rates of complete ablation, local recurrence, disease-free and cumulative survival (at 1, 2, 3, and 4 years), and major complications were not significantly different between groups. In another 2013 study by Ding et al, complications were retrospectively compared between 556 patients treated with MWA for 1,090 tumors (491 HCC, 18 cholangiocarcinoma, 47 liver metastases) and 323 patients treated with RFA for 562 liver tumors (279 HCC, 6 cholangiocarcinoma, 38 liver metastases). (11) Rates of death (2/556 MWA, 1/323 RFA patients), major complications and minor complications did not differ significantly between MWA and RFA groups.

In 2011, Zhou et al. prospectively evaluated percutaneous MWA for HCC in 215 patients with tumors of 60 mm or less (median size, 29 mm) in a single center, Phase II study. (12) The authors reported technical effectiveness in all patients. OS rates at 1, 2, 3, 4, and 5 years were 94%, 82.9%, 66%, 54.1%, and 44.4%, respectively, and median survival time was 40 months (range, 4-106 months). Complications related to the procedure included 3 cases of pleural effusion and one case of bile duct injury. In another prospective study by Zhou et al. in 2009, percutaneous MWA was performed on 124 patients with 144 HCC lesions and 28 patients with 35 lesions of hepatic metastases. (13) Included in this total of 152 patients were 59 patients with 61 lesions (mean size, 27 mm) located less than 5 mm from the gastrointestinal tract and 93 patients with 126 lesions (mean size 24 mm) located more than 5 mm from the gastrointestinal tract. For lesions less than 5 mm from the gastrointestinal tract, the temperatures of the margins were monitored closely during ablation and to prevent thermal injury, ethanol injections were placed into marginal tumor tissue in 33 lesions that were protruding or in contact with the gastrointestinal tract. No procedural complications were noted; however, tumor seeding occurred in 3 patients. Complete ablation was achieved in 47 of 53 lesions (88.7%) in the group with tumors near the gastrointestinal tract and in 116 of the other 126 lesions (92.1%), as confirmed by imaging during the follow-up period ranging from 3 to 32 months. Local tumor progression occurred in 16 tumors during 1- to 9 -month follow-up. Separate treatment outcomes for hepatocellular tumors and hepatic metastasis were not provided.

Lu et al., in 2005, reported on a retrospective comparison of 102 patients with HCC treated with either percutaneous MWA (49 patients with 98 nodules; mean size, 2.5 cm) or RFA (53 patients with 72 nodules; mean size, 2.6 cm). (7) Patient follow-up was 25.1 months in the MWA group and 24.8 months in the RFA group. Complete ablation was not significantly different in the treatment groups and was achieved in 93 of 98 tumors (94.9%) in the MWA group and in 67 of 72 tumors (93.1%) in the RFA group. However, complete ablation rates increased in tumors less than or up to 3 cm in size to 98.6% (73/74) in the MWA group and 98% (50/51) in the RFA group. In tumors greater than 3 cm, complete ablation rates decreased to 83.3% (20/24) in the MWA group and 81% (17/21) in the RFA group. There were also no significant differences found in the MWA group versus the RFA group in rates of local tumor recurrence (11.8% vs. 20.9%, respectively), major complications (8.2% vs. 5.7%, respectively) or disease-free survival at 1, 2, and 3 years (45.9%, 26.9%, and 26.9% vs. 37.2%, 20.7%, and 15.5%, respectively).

In 2012, Takami et al. reported on 719 patients treated with intraoperative MWA for HCC (mean tumor size, 26.9 mm) at a single institution. (14) The OS rates were 97.7% at 1 year, 62.1% at 5 years, and 34.1% at 10 years. OS rates for 390 patients with 3 or fewer tumors measuring 3 cm or less were 97.9% at 1 year, 70.0% at 5 years, and 43.0% at 10 years. When MWA results were compared with 34 patients treated at the same institution with hepatic resection, OS, disease-free survival, and local recurrence rates were not significantly different.

In 2009, Liang et al. reported on a retrospective review of complications experienced with percutaneous MWA for the treatment of 1,928 malignant liver tumors in 1,136 patients at a single institution. (8) Each patient received an average of 1.8 treatment sessions for a total of 3,697 treatment sessions. Thirty patients (2.6%) experienced major complications, which included 5 cases of liver abscess and empyema, 2 bile duct injuries, 2 colon perforations, 5 tumor seedings, 12 pleural effusions requiring thoracentesis, 1 hemorrhage requiring arterial embolization, and 3 skin burns requiring resection for a total of 30 (2.6%) patient complications. Two deaths occurred within 30 days after MWA in patients with Child class B uncompensated cirrhosis. One patient (age 78) had multi-organ failure and died 14 days after treatment and another patient (age 83) had respiratory and cardiac failure and died 14 days after treatment. Minor complications included fever (83.4%), pain (80.1%), asymptomatic pleural effusion (10.4%), thickening of the gallbladder wall (2.8%), and arterioportal shunt (0.3%), small stricture of the bile duct (0.4%), and skin burn requiring no treatment (1.6%). A significantly higher rate of major complications and more ablation sessions were experienced when a noncooled-shaft antenna was used during the period of 1994 to 2005 (n=583) than with newer technology; cooled-shaft antennas were used beginning in 2005 (n=583). In a report on needle-track seeding from this same institution, Yu et al. followed 1,462 patients treated with percutaneous MWA for 2,530 liver tumors over a 14-year period. (15) Twelve seeding nodules with a mean size of 2.3±0.7 cm (range, 1.3-3.9 cm) were found in 11 patients within 6 to 37 months (median 10 months) after receiving MWA.

Hepatic Metastasis from Primary Cancers from Other Sites

The literature searches identified many small studies on MWA for hepatic metastases, 1 RCT, and several systematic reviews. (5,6,16-18) A 2014 Health Technology Assessment (18) and a 2013 Cochrane review (17) also identified only 1 RCT on ablation for liver metastasis, Shibata et al., (19) (described next). The reviewers found insufficient evidence to determine any benefits of MWA for liver metastasis over surgical resection. In the Ong systematic review (previously described) local recurrence rates for liver metastases after treatment with MWA averaged approximately 15% but varied between 0% and 50% in the 7 studies reviewed that addressed liver metastases. As noted earlier, Ong et al. concluded MWA is a promising treatment option for the treatment of liver tumors but should be reserved for patients not amenable to hepatic resection. Bertot et al. conducted a systematic review, also described earlier. (6) In 2011, Pathak et al. conducted a systematic review of ablation techniques for colorectal liver metastases, which included 13 studies on MWA totaling 406 patients with a minimum of 1-year follow-up. (16) Mean survival rates were 73%, 30%, and 16% and ranged from 40% to 91.4%, 0% to 57%, and 14% to 32% at 1-, 3-, and 5-year follow-up, all respectively. Minor and major complication rates were considered acceptable and ranged from 6.7% to 90.5% and 0% to 19%, respectively. Local recurrence rates ranged from 2% to 14%. The authors acknowledged limitations in the available studies but concluded that survival rates for MWA are more favorable than for palliative chemotherapy alone.

Only one RCT comparing the use of MWA for hepatic metastases to the criterion standard of surgical resection was identified. In 2000, Shibata et al. reported on a trial of 30 patients with hepatic metastases from colorectal cancer randomly assigned without stratification to treatment with either MWA after laparotomy (n=14) or hepatectomy (n=16). (19) The study began with 40 patients, but 10 patients were excluded because the researchers discovered intraoperatively that these patients did not meet study criteria due to having extensive metastasis or 10 or more tumors. The treatment groups of MWA versus hepatectomy were not significantly different in age (mean age, 61 years in both groups) number of tumors (mean 4.1 vs. 3.0, respectively) or tumor size (mean 27 mm vs. 34 mm, respectively). The authors reported no significant differences in survival rates following MWA or hepatectomy (27 months vs. 25 months, respectively) and mean disease-free survival (11.3 vs. 13.3 months, respectively). However, intraoperative blood loss was significantly lower and no blood transfusions were required in the MWA group, whereas 6 patients in the hepatectomy group required blood transfusions. Complications in the microwave group consisted of one hepatic abscess and one bile duct fistula. In the hepatectomy group, complications were one intestinal obstruction, one bile duct fistula, and wound infection.

In 2011, Lorentzen et al. reported on a retrospective review of percutaneous or open MWA in 39 patients with 125 liver metastases from the primary sites of colorectal cancer (n=31), breast cancer (n=6), carcinoid tumor (n=1), and gastrointestinal stromal tumor (n=1). (20) Complete ablation was achieved in 100% of tumors (median size, 1.5 cm) with one treatment session in 34 patients, 2 sessions for 4 patients, and 3 sessions for one patient. One case of liver abscess, which resolved after percutaneous drainage, was the only major complication reported. Four minor complications included one incidence of ascites and 3 complaints of puncture site pain. At median follow-up of 11 months, local tumor progression was seen in 12 of 125 tumors (9.6%) in 10 of the 39 patients (26%).

In a prospective, single institution Phase II study in 2010, Martin et al. reported on 100 patients treated with 270 open or laparoscopic MWAs for HCC (n=17) and liver metastases from the primary sites of colorectal (n=50), carcinoid (n=11), and other cancers (n=22 and included cholangiocarcinoma, metastatic breast, renal cell carcinoma, bladder, carcinoid, melanoma, and sarcoma). (21) Median tumor size was 3.0 cm. Thirty-eight patients were treated with MWA alone, 53 patients had MWA with concomitant hepatic resection while another 9 patients had MWA concomitant with other organ resection. Only 2 patients had incomplete ablations after the procedure. No bleeding complications were experienced, but 2 cases of hepatic abscess and 2 cases of hepatic insufficiency occurred. At median follow-up of 36 months, 5 patients were found to have incomplete ablations and only 2 patients (2%) had local tumor recurrence, while 37 patients (37%) developed recurrence at other nonablated sites.

In 2013, Liu et al. reported on 35 patients treated with MWA for 62 tumors and 54 patients treated with RFA for 70 tumors from liver metastases. (22) Ablation was complete in 88.6% (117/132) of tumors and was not significantly different between tumor types: 86.2% for metastatic colorectal cancer (56/65) and 91% for other metastatic disease 61/67). Nor was there a significant difference between MWA and RFA in the complete ablation rate. Tumors 3.0 cm or less were completely ablated significantly more often than tumors greater than 3.0 cm (93.5 vs. 66.7%, p=0.001).

Lung

Several studies have reported experience using MWA for lung tumors. (23-25) In 2012, Lu et al. reported on a retrospective review of 69 patients treated with MWA for inoperable lung cancer or metastatic pulmonary metastases. (26) OS rates for patients with pulmonary metastases at 1year, 2years, and 3years were 47.6%, 23.8%, and 14.3%, respectively. The recurrence-free survival rates for patients with non-small cell lung cancer at 1year, 2years, and 3years were 72.9%, 50.0%, and 27.1%, respectively. OS rates were 66.7% at 1 year, 44.9% at 2 years, and 24.6% at 3 years. No deaths occurred within 30 days of the procedure; however, pneumothorax occurred in 24.64%. In 2012, Belfiore et al. reported on a retrospective review of 56 patients treated with MWA for inoperable lung cancer or metastatic pulmonary metastases. (27) Disease-specific survival rates were 69% at 1 year, 54% at 2 years, and 49% at 3 years. Pneumothorax was reported in 18 patients (32.12%). In 2011, Vogl et al. reported on a prospective study of 80 patients treated with MWA for inoperable pulmonary metastases. (28) Survival rates were 91.3% at 1 year and 75% at 2 years. No deaths occurred within 60 days of the procedure; however, pneumothorax occurred in 11 of 130 MWA sessions (8.5%), and pulmonary hemorrhage occurred in 8 of 130 sessions (6.2%).

Primary Renal Tumors

In a 2014 systematic review and meta-analysis, Katsanos et al. compared thermal ablation (MWA and RFA) with surgical nephrectomy for small renal tumors (mean size 2.5 cm). (29) Included in the analysis were 1 randomized study on MWA30 (described next) and 5 cohort studies on RFA with a total of 587 patients. In the ablation group, the complication rates and renal function decline were significantly lower than in the nephrectomy group (p=0.04 and p=0.03, respectively). The local recurrence rate was 3.6% in both groups (risk ratio=0.92, 95% CI, 0.4 to 2.14, p=0.79) and disease-free survival up to 5 years was not significantly different between groups (hazard ratio=1.04, 95% CI, 0.48 to 2.24, p=0.92).

Martin et al reported on a meta-analysis of MWA versus cryoablation for small renal tumors in 2013. (31) Included in the analysis were 7 MWA studies (n=164) and 44 cryoablation studies (n=2989). The studies were prospective or retrospective, nonrandomized, noncomparative studies. The mean follow-up duration was shorter for MWA than cryoablation (17.86 months vs 30.22 months, p=0.07). While the mean tumor size was significantly larger in the MWA studies than the cryoablation studies (2.58 cm vs 3.13 cm, respectively, p=0.04), local tumor progression (4.07% vs 2.53%, respectively; p=0.46), and progression to metastatic disease (0.8% vs 0%, respectively; p=0.12) were not significantly different.

In 2012, Guan et al reported on a prospective randomized study to compare the use of MWA with partial nephrectomy (the criterion standard of nephron-sparing surgical resection) for solitary renal tumors less than 4 cm. (30) Forty-eight patients received MWA and 54 had partial nephrectomy. Patients in the MWA group had significantly fewer postoperative complications than the partial nephrectomy group (6 [23.5%] vs. 18 [33.3%]; p=0.019). MWA patients also had significantly less postoperative renal function declines (p<0.009) and estimated perioperative blood loss (p<0.001) than partial nephrectomy patients. At last follow-up, estimated glomerular filtration rate declines in both groups were similar (p=1.000). Disease-specific deaths did not occur, and overall local recurrence-free survival by Kaplan-Meier estimates at 3 years were 91.3% for MWA and 96.0% for partial nephrectomy (p=0.541). Longer follow-up is needed.

Several small case studies on renal tumors have been reported. In 2012, Yu et al. reported on a retrospective review of 46 patients treated with MWA for renal cell carcinoma. (32) Complete ablation occurred in 98% of tumors (48 of 49), which had a mean tumor size of 3.0±1.5 cm. At a median follow-up of 20.1 months, all 46 patients were metastasis-free. OS rates were 100% at 1 and 2 years and 97.8% at 3 years.

In 2011, Muto et al. reported complete tumor coagulation necrosis in 10 patients treated with laparoscopic MWA for clear cell renal carcinoma with a median tumor size of 2.75 cm. (33) Depending on tumor size, the microwave antennas were used 1 to 3 times for a mean application time of 14.1 minutes. No complications were reported during or after the procedure. Bai et al. in 2010, reported complete laparoscopic MWA in 17 of 18 clear cell renal carcinoma tumors with a mean tumor size of 2.8 cm. (34) In this study, evidence of disease progression was not found in any of the patients followed up for a median of 20 months, including the patient with an incomplete ablation who was followed for 31 months. Complications reported were mild (18.2%), and renal function did not significantly deteriorate. However, in a 2011 study of 10 patients with solid-enhancing renal tumors (median size of 3.65 cm), treated with laparoscopic (n=7) or percutaneous (n=3) MWA, Castle et al. reported tumor recurrence was seen in 3 of 8 tumors on mean follow-up time of 17.9 months. (35) Because tumor size was larger in this study, mean ablation time was 21 minutes. Additionally, 20% of patients experienced intraoperative complications while 40% experienced postoperative complications including, perinephric hematoma, splenic capsular tear, pleuritic chest pain, skin burn, fever, hematuria, genitofemoral neuralgia, and urinoma.

In another study, Guan et al. reported on the safety of retroperitoneoscopic MWA for renal hamartoma in 2010. (36) In this case series report, 15 of 16 patients had complete tumor ablation. Disease recurrence was not found in all 16 patients at a median follow-up of 16 months.

Other Tumors or Conditions

No RCTs on the use of MWA for other tumors or conditions were identified. Case studies and retrospective reviews on MWA for adrenal carcinoma, (37) metastatic bone tumors, (38) intrahepatic primary cholangiocarcinoma, (39) benign thyroid tumors, (40) and other non-oncologic conditions (i.e., bleeding peptic ulcers, esophageal varices, secondary hypersplenism) were identified.

A systematic review of ablation therapies, including MWA, for locally advanced pancreatic cancer was published in 2014. (41) The reviewers found limited available evidence on MWA for pancreatic cancer. Therefore, without randomized studies, no conclusions could be drawn on thermal ablation methods for pancreatic cancer.

Ongoing and Unpublished Clinical Trials

A September 16, 2014, a search of online site ClinicalTrials.gov identified one randomized trial on MWA. In this Phase III, prospective RCT, MWA will be compared with RFA in the treatment of unresectable HCC no more than 6 cm in diameter (NCT01340105). Patients may only have up to 3 nodules that are amenable to ablation and do not have any major vascular or bile duct invasion. Patients with resectable tumors may be included in the study if local ablation is preferred. The trial began in April 2011 in Hong Kong, China and expects to recruit 92 patients. This study is expected to be completed in April 2016.

Clinical Input Received from Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

2011

In response to requests, input was received from 2 physician specialty societies (3 reviews) and 4 academic medical centers (6 reviews) while this policy was under development. Eight reviewers considered microwave ablation investigational to treat primary tumors such as HCC, benign and malignant renal tumors, lung tumors, adrenal tumors or cholangiocarcinoma. The reviewers noted insufficient evidence and a need for further studies on microwave ablation. However, 1 reviewer indicated microwave ablation for primary tumors including, but not limited to HCC, benign and malignant renal tumors, lung tumors, adrenal tumors and cholangiocarcinoma, may be considered a treatment option and 1 other reviewer indicated microwave ablation for renal tumors may be considered a treatment option.

Four reviewers considered microwave ablation investigational to treat liver metastases. However, 2 reviewers indicated microwave ablation for liver metastases may be considered a treatment option. One reviewer noted microwave ablation may be appropriate for tumors not amenable to RFA or other local treatments. This reviewer also indicated microwave ablation may be more appropriate for tumors located near large blood vessels.

Summary of Evidence

Based on review of the published data (which consist largely of small case series and limited randomized trials) and clinical input, there is insufficient evidence to permit conclusions concerning the comparative effectiveness of microwave ablation (MWA) to other ablative techniques on health outcomes. Therefore, MWA of hepatocellular carcinoma (HCC), liver metastases from primary cancers from other sites, renal cell carcinoma, other renal tumors and all other tumors is considered investigational.

Studies show MWA results in a wide range of complete tissue ablation (50%-100%) depending on tumor size with complete ablation common and nearing 100% with smaller tumors (e.g., ≤3 cm). Recurrence of tumors at ablated sites is very low. However, recurrence of tumors at nonablated sites is common and may be due to the nature of the disease state (e.g., in HCC). Intraoperative and postoperative minor and major complications are low, especially in cases where tumors are smaller and more accessible. While some earlier studies found MWA required more treatment sessions to achieve adequate ablation, more recent studies using newer MWA technology that deliver larger ablation zones with cooled-shaft antennas have demonstrated shorter ablation times and fewer complications. While MWA has theoretical advantages over radiofrequency ablation (RFA), studies on the use of MWA with larger numbers of patients and longer follow-up are needed to adequately assess health outcomes. Patient selection criteria and rationale for using MWA over other established techniques such as surgical resection or RFA are needed. Results of the ongoing Phase III trial comparing MWA to RFA will provide additional information in determining the role of MWA in the treatment of HCC. Information from additional future studies may indicate a role for MWA for the treatment of tumors for control of local tumor growth, palliation of symptoms, and extended survival durations in tumors that are not amenable to resection or in patients who are not surgical candidates. However, in total, the current available evidence is insufficient to permit conclusions on net health outcomes of MWA of tumors, and this technique is considered investigational.

Practice Guidelines and Position Statements

The National Comprehensive Cancer Network guidelines on hepatobiliary cancers lists MWA (along with RFA, cryoablation, and percutaneous alcohol injection) as a treatment option for HCC tumors in patients who are not candidates for potential curative treatments (e.g., resection and transplantation) and do not have large-volume extrahepatic disease. (42) Ablation should only be considered when tumors are accessible by percutaneous, laparoscopic, or open approaches The guidelines indicate HCC tumors of 3 centimeters or less may be curatively treated with ablation alone. HCC tumors between 3 and 5 centimeters may also be treated with ablation to prolong survival when used in combination with arterial embolization. Additionally, the tumor location must be accessible to permit ablation of the tumor and tumor margins without ablating major vessels, bile ducts, the diaphragm or other abdominal organs. However, there are only 2 reviews cited in the guideline on ablative techniques to support these recommendations, but these reviews are not specific to MWA [category 2A].

In the NCCN guidelines on neuroendocrine tumors, MWA is listed as one treatment option (along with RFA or cryoablation) for liver metastases as hepatic regional therapy in carcinoid tumors and pancreatic endocrine (islet cell) tumors when there is unresectable disease and/or distant metastases. (43) These guidelines note, currently, there are limited prospective data and no RCTs on ablative therapies (including MWA), and data on these ablative techniques are emerging. Additionally, the 2 articles cited in the guideline on ablative techniques are not specific to MWA [category 2B].

The National Institute for Health and Clinical Excellence (NICE) published updated guidance on MWA for the Treatment of Metastases in the Liver in August 2011. (44) This guidance indicates “Current evidence on microwave ablation for the treatment of liver metastases raises no major safety concerns. The evidence on efficacy is inadequate in quantity and quality. Therefore this procedure should only be used with special arrangements for clinical governance, consent and audit or research.” NICE also published guidance on MWA for HCC in 2007. (45) This guidance indicates “Current evidence on the safety and efficacy of microwave ablation of hepatocellular carcinoma appears adequate to support the use of this procedure provided that the normal arrangements are in place for consent, audit and clinical governance.” The guidance also states there are no major concerns regarding the efficacy of MWA but notes there is limited long-term survival data available.

The American College of Chest Physicians 2013 evidence-based guidelines on the treatment of non-small cell lung cancer (NSCLC) (46) note that the role of ablative therapies in the treatment of high-risk patients with stage I NSCLC is evolving. RFA, the most studied of the ablative modalities, has been used effectively in medically inoperable patients with small (<3 cm) peripheral NSCLC that are clinical stage I.

U.S. Preventive Services Task Force Recommendations

Microwave tumor ablation is not a preventive service.

Medicare National Coverage

There is no national coverage determination (NCD). In the absence of an NCD, coverage decisions are left to the discretion of local Medicare carriers.

References

  1. Zhao Z, Wu F. Minimally-invasive thermal ablation of early-stage breast cancer: a systemic review. Eur J Surg Oncol. Dec 2010; 36(12):1149-1155. PMID 20889281
  2. Zhou W, Zha X, Liu X, et al. US-guided percutaneous microwave coagulation of small breast cancers: a clinical study. Radiology. May 2012; 263(2):364-373. PMID 22438362
  3. Shibata T, Iimuro Y, Yamamoto Y, et al. Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology. May 2002; 223(2):331-337. PMID 11997534
  4. Taniai N, Yoshida H, Mamada Y, et al. Is intraoperative adjuvant therapy effective for satellite lesions in patients undergoing reduction surgery for advanced hepatocellular carcinoma? Hepatogastroenterology. Mar-Apr 2006; 53(68):258-261. PMID 16608035
  5. Ong SL, Gravante G, Metcalfe MS, et al. Efficacy and safety of microwave ablation for primary and secondary liver malignancies: a systematic review. Eur J Gastroenterol Hepatol. Jun 2009; 21(6):599-605. PMID 19282763
  6. Bertot LC, Sato M, Tateishi R, et al. Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: a systematic review. Eur Radiol. Dec 2011; 21(12):2584-2596. PMID 21858539
  7. Lu MD, Xu HX, Xie XY, et al. Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study. J Gastroenterol. Nov 2005; 40(11):1054-1060. PMID 16322950
  8. Liang P, Wang Y, Yu X, et al. Malignant liver tumors: treatment with percutaneous microwave ablation--complications among cohort of 1136 patients. Radiology. Jun 2009; 251(3):933-940. PMID 19304921
  9. Simo KA, Sereika SE, Newton KN, et al. Laparoscopic-assisted microwave ablation for hepatocellular carcinoma: Safety and efficacy in comparison with radiofrequency ablation. J Surg Oncol. Dec 2011; 104(7):822-829. PMID 21520094
  10. Ding J, Jing X, Liu J, et al. Comparison of two different thermal techniques for the treatment of hepatocellular carcinoma. Eur J Radiol. Sep 2013; 82(9):1379-1384. PMID 23726122
  11. Ding J, Jing X, Liu J, et al. Complications of thermal ablation of hepatic tumours: comparison of radiofrequency and microwave ablative techniques. Clin Radiol. Jun 2013; 68(6):608-615. PMID 23399463
  12. Zhou P, Liang P, Dong B, et al. Long-term results of a phase II clinical trial of superantigen therapy with staphylococcal enterotoxin C after microwave ablation in hepatocellular carcinoma. Int J Hyperthermia. 2011; 27(2):132-139. PMID 21117923
  13. Zhou P, Liang P, Yu X, et al. Percutaneous microwave ablation of liver cancer adjacent to the gastrointestinal tract. J Gastrointest Surg. Feb 2009; 13(2):318-324. PMID 18825464
  14. Takami Y, Ryu T, Wada Y, et al. Evaluation of intraoperative microwave coagulo-necrotic therapy (MCN) for hepatocellular carcinoma: a single center experience of 719 consecutive cases. J Hepatobiliary Pancreat Sci. Jun 19 2012. PMID 22710886
  15. Yu J, Liang P, Yu XL, et al. Needle track seeding after percutaneous microwave ablation of malignant liver tumors under ultrasound guidance: analysis of 14-year experience with 1462 patients at a single center. Eur J Radiol. Oct 2012; 81(10):2495-2499. PMID 22137097
  16. Pathak S, Jones R, Tang JM, et al. Ablative therapies for colorectal liver metastases: a systematic review. Colorectal Dis. Sep 2011; 13(9):e252-265. PMID 21689362
  17. Bala MM, Riemsma RP, Wolff R, et al. Microwave coagulation for liver metastases. Cochrane Database Syst Rev. 2013;10:CD010163. PMID 24122576
  18. Loveman E, Jones J, Clegg AJ, et al. The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluation. Health Technol Assess. Jan 2014;18(7):vii-viii, 1-283. PMID 24484609
  19. Shibata T, Niinobu T, Ogata N, et al. Microwave coagulation therapy for multiple hepatic metastases from colorectal carcinoma. Cancer. Jul 15 2000; 89(2):276-284. PMID 10918156
  20. Lorentzen T, Skjoldbye BO, Nolsoe CP. Microwave Ablation of Liver Metastases Guided by Contrast-Enhanced Ultrasound: Experience with 125 Metastases in 39 Patients. Ultraschall Med. Oct 2011; 32(5):492-496. PMID 21259183
  21. Martin RC, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol. Jan 2010; 17(1):171-178. PMID 19707829
  22. Liu Y, Li S, Wan X, et al. Efficacy and safety of thermal ablation in patients with liver metastases. Eur J Gastroenterol Hepatol. Apr 2013; 25(4):442-446. PMID 23470267
  23. Wolf FJ, Grand DJ, Machan JT, et al. Microwave ablation of lung malignancies: effectiveness, CT findings, and safety in 50 patients. Radiology. Jun 2008; 247(3):871-879. PMID 18372457
  24. Carrafiello G, Mangini M, Fontana F, et al. Complications of microwave and radiofrequency lung ablation: personal experience and review of the literature. Radiol Med. Oct 21 2012; 117(2):201-213. PMID 22020434
  25. He W, Hu XD, Wu DF, et al. Ultrasonography-guided percutaneous microwave ablation of peripheral lung cancer. Clin Imaging. Jul-Aug 2006; 30(4):234-241. PMID 16814137
  26. Lu Q, Cao W, Huang L, et al. CT-guided percutaneous microwave ablation of pulmonary malignancies: results in 69 cases. World J Surg Oncol. 2012; 10:80. PMID 22564777
  27. Belfiore G, Ronza F, Belfiore MP, et al. Patients' survival in lung malignancies treated by microwave ablation: our experience on 56 patients. Eur J Radiol. Jan 2013; 82(1):177-181. PMID 23099201
  28. Vogl TJ, Naguib NN, Gruber-Rouh T, et al. Microwave ablation therapy: clinical utility in treatment of pulmonary metastases. Radiology. Nov 2011; 261(2):643-651. PMID 22012906
  29. Katsanos K, Mailli L, Krokidis M, et al. Systematic review and meta-analysis of thermal ablation versus surgical nephrectomy for small renal tumours. Cardiovasc Intervent Radiol. Apr 2014;37(2):427-437. PMID 24482030
  30. Guan W, Bai J, Liu J, et al. Microwave ablation versus partial nephrectomy for small renal tumors: intermediate-term results. J Surg Oncol. Sep 1 2012; 106(3):316-321. PMID 22488716
  31. Martin J, Athreya S. Meta-analysis of cryoablation versus microwave ablation for small renal masses: is there a difference in outcome? Diagn Interv Radiol. Nov-Dec 2013;19(6):501-507. PMID 24084196
  32. Yu J, Liang P, Yu XL, et al. US-guided percutaneous microwave ablation of renal cell carcinoma: intermediate-term results. Radiology. Jun 2012; 263(3):900-908. PMID 22495684
  33. Muto G, Castelli E, Migliari R, et al. Laparoscopic microwave ablation and enucleation of small renal masses: preliminary experience. Eur Urol. Jul 2011; 60(1):173-176. PMID 21531501
  34. Bai J, Hu Z, Guan W, et al. Initial experience with retroperitoneoscopic microwave ablation of clinical T(1a) renal tumors. J Endourol. Dec 2010; 24(12):2017-2022. PMID 20932080
  35. Castle SM, Salas N, Leveillee RJ. Initial experience using microwave ablation therapy for renal tumor treatment: 18-month follow-up. Urology. Apr 2011; 77(4):792-797. PMID 21324512
  36. Guan W, Bai J, Hu Z, et al. Retroperitoneoscopic microwave ablation of renal hamartoma: middle-term results. J Huazhong Univ Sci Technol Med Sci. Oct 2010; 30(5):669-671. PMID 21063854
  37. Li X, Fan W, Zhang L, et al. CT-guided percutaneous microwave ablation of adrenal malignant carcinoma: Preliminary results. Cancer. Nov 15 2011; 117(22):5182-5188. PMID 21523760
  38. Pusceddu C, Sotgia B, Fele RM, et al. Treatment of bone metastases with microwave thermal ablation. J Vasc Interv Radiol. Feb 2013; 24(2):229-233. PMID 23200605
  39. Yu MA, Liang P, Yu XL, et al. Sonography-guided percutaneous microwave ablation of intrahepatic primary cholangiocarcinoma. Eur J Radiol. Nov 2011; 80(2):548-552. PMID 21300500
  40. Yue W, Wang S, Wang B, et al. Ultrasound guided percutaneous microwave ablation of benign thyroid nodules: Safety and imaging follow-up in 222 patients. Eur J Radiol. Aug 30 2013; 82(1):e11-16. PMID 22940229
  41. Keane MG, Bramis K, Pereira SP, et al. Systematic review of novel ablative methods in locally advanced pancreatic cancer. World J Gastroenterol. Mar 7 2014;20(9):2267-2278. PMID 24605026
  42. National Comprehensive Cancer Network. Hepatobiliary Cancers. Clinical practice guidelines in oncology, v.2.2014. http://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed August 13, 2014.
  43. National Comprehensive Cancer Network. Neuroendocrine Tumors. Clinical practice guidelines in oncology, V.2.2014 http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Accessed August 13, 2014.
  44. National Institute for Clinical Excellence (NICE). Microwave Ablation for the Treatment of Metastases in the Liver. IPG406. 2011; http://www.nice.org.uk/nicemedia/live/11333/56036/56036.pdf. Accessed August 13, 2014.
  45. National Institute for Clinical Excellence (NICE). Microwave Ablation of Hepatocellular Carcinoma IPG214. 2007; http://publications.nice.org.uk/microwave-ablation-of-hepatocellular-carcinoma-ipg214. Accessed August 13, 2014.
  46. Howington J, Blum M, Chang A, et al. Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest May 2013;143(5 Suppl):e278S-313S. PMID 23649443

Coding

Codes

Number

Description

CPT

19499

Unlisted procedure, breast

 

32998

Ablation therapy for reduction or eradication of 1 or more pulmonary tumor(s) including pleura or chest wall when involved by tumor extension, percutaneous, radiofrequency, unilateral

 

47379

Unlisted laparoscopic procedure, liver

 

47382

Ablation, 1 or more liver tumor(s), percutaneous, radiofrequency

 

47399

Unlisted procedure, liver

 

50592

Ablation, 1 or more renal tumor(s), percutaneous, unilateral, radiofrequency

 

53899

Unlisted procedure, urinary system (for renal tumors)

 

60699

Unlisted procedure, endocrine system (for adrenal or thyroid tumors)

 

76940

Ultrasound guidance for, and monitoring of, parenchymal tissue ablation

Type of Service

Surgery

 

Place of Service

Outpatient

Inpatient

 

Appendix

N/A

History

Date

Reason

02/27/12

New Policy – Add to Surgery section. Policy created with literature review through October 2011; investigational for all tumors.

07/31/12

Code 47379 added to the policy as this procedure can be performed laparoscopically

09/07/12

Update coding section – ICD-10 codes are now effective 10/01/14.

12/20/12

Update Related Policies; policy number 7.01.540 was replaced with 7.01.95.

04/16/13

Replace policy. Policy updated with literature review; reference numbers 2, 12-13, 21-25, 32 and 36 added. Policy statement unchanged.

12/09/13

Replace policy. Policy Guidelines reformatted for readability. Rationale updated with literature review through August 2013. References 10, 11, 20, 34 added; others renumbered/removed. Policy statement unchanged.

03/11/14

Coding Update. Code 55.33 was removed per ICD-10 mapping project; this code is not utilized for adjudication of policy.

12/17/14

Annual Review. Policy updated with literature review through September 15, 2014, reference numbers 17-18, 29 and 31 added. Reference 46 updated. Policy statement unchanged. ICD-9 and ICD-10 diagnosis and procedure codes removed; these do not relate to policy adjudication.


Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA).
©2015 Premera All Rights Reserved.